Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from May 25, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 23, 2026 — +5.3% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$42.41 – $43.87Entry zone — fair-value band

$44.39Published — price the day we called it

$46.90Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$46.74Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 31 days.

At window close

+5.3%

realized, from the publication price to the last close inside the window

Peak gain

+15.9%

peak, from the publication price — not a realized return

S&P 500, same window

+3%

SPY over the identical days, dividend-adjusted

Window close

$46.74

last close inside the window, ended August 23, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

The thesis — published May 25, 2026

Predicted growth

+7%

over the measurement window

Target price

$46.90

the price the thesis aimed for

Entry zone

$42.41 – $43.87

the fair-value band we waited for

Price at publication

$44.39

published May 25, 2026

Confidence

71%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk offers steady exposure to healthcare because its diabetes and obesity treatments keep selling. The stock looks fairly valued and tends not to swing with the market, which makes gains likely to be modest. Recent competitive drug news and a weak earnings report mean the near-term outlook is cautious rather than fast growth.

Primary drivers

Strong ongoing demand for diabetes and obesity medicines
Reasonable valuation makes the stock a defensive option
Lower sensitivity to market swings reduces volatility in portfolios
Recent rival drug news limits near-term upside potential

How it played out

NVO: target reached in 31 days

Lyra published NVO at 44.39 with an expected gain of 7% and a target of 46.90. The thesis pointed to continuing demand for diabetes and obesity medicines, a reasonable valuation, and lower sensitivity to market swings. It also cited rival drug news as a limit on near-term upside and expected modest gains.

The stock reached the target in 31 days. It later peaked at 51.46 on July 29, a gain of 15.9%. NVO ended the window at 46.74, below the target but above the publication price. The thesis played out and exceeded its stated expectation.

What happened during the window

On July 15, Novo Nordisk said the European Commission had approved its Wegovy pill for weight management. On August 4, the company reported that adjusted second-quarter sales rose 7% at constant exchange rates and raised its full-year adjusted outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals